Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...

In a dynamic environment, an expert shares insights into potential AI applications in the clinical research setting at OCT ...